Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis (RENTGPA)

March 20, 2018 updated by: Hospital for Special Surgery, New York
This is a phase IV, single-center, randomized, placebo-controlled pilot study that will evaluate the efficacy of rituximab at inducing otolaryngologic remission in GPA patients with active otolaryngologic disease.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Patients with GPA and active ENT disease in at least two ENT domains, as defined after endoscopic visualization of the upper airway and audiometric evaluation by a single otolaryngologist using a validated GPA ENT disease activity score, will be eligible for inclusion. ENT disease may be new, grumbling or relapsing.

All patients entering the trial will receive standard induction therapy with rituximab (375mg/m2 per week x 4). At week 16, patients will be randomized to receive maintenance rituximab (1000mg) every 4 months or placebo infusions. The primary outcome will be assessed at week 52. Patients will be treated with a standardized prednisone taper according to whether they had severe or limited disease at study entry, prednisone taper will be completed at week 16.

The investigators plan to enroll 28 patients who will be randomized in a 1:1 fashion to rituximab or placebo. The investigators estimate accrual of these subjects will take 18 months from study initiation. Once enrolled, subjects are followed for 52 weeks until the primary endpoint is assessed.

Study Type

Interventional

Enrollment (Actual)

3

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 100214898
        • Hospital for Special Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

GPA Specific Inclusion:

  1. Patients must have met at least 2 of the 5 modified ACR classification criteria for GPA. These do not need to be present at the time of study entry. The modified ACR criteria are:

    • Nasal or oral inflammation, defined as the development of painful or painless oral ulcers or purulent or bloody nasal discharge
    • Abnormal chest radiograph, defined as the presence of nodules, fixed infiltrates, or cavities
    • Active urinary sediment, defined as microscopic hematuria (>5 red blood cells per high power field) or red blood cell casts
    • Granulomatous inflammation on biopsy, defined as histologic changes showing granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area (artery or arteriole)
    • Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for proteinase-3, measured by enzyme-linked immunoassay

  2. Active GPA in the ENT domain within 1 month prior to screening, where the active disease is defined as a score of ≥2 on a GPA ENT disease activity score (7 items scored as 1= present 0= absent) performed by direct endoscopic visualization of the upper airway and audiometric evaluation by a single expert otolaryngologist. Items included in the GPA ENT disease activity score are:

    • Bloody rhinorrhea (Daily blood stained nasal discharge)
    • Objective stridor (Stridor assessed by doctor)
    • Inflammation on nasal examination (Ulcers, granulation, friable mucosa on rigid nasendoscopy. Excluding crusting)
    • Inflammation on flexible laryngoscopy (Ulcers, granulation, friable mucosa in the larynx)
    • Inflamed TM*/middle ear (Persistent inflammation or granulation tissue in tympanic membrane/middle ear)
    • Sudden sensorineural hearing loss (30db drop in 3 frequencies within 72 hours)
    • Other ENT/upper airway manifestations of active GPA observed during structured ENT exam including but not limited to lacrimal gland dacryocystitis and endobronchial disease

    General Medical Concerns:

  3. Age 18 and older
  4. Willing and able to comply with treatment and follow-up procedures
  5. Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment.
  6. Willing and able to provide written informed consent

Rituximab-Specific Concerns:

  • ANC: > 1000/mm3
  • Platelets: > 100,000/mm3
  • Hemoglobin: > 7 gm/dL
  • Adequate renal function as indicated by Cr >4.0mg/dl
  • Adequate liver function as defined by AST or ALT <2x Upper Limit of Normal unless related to primary disease.

Exclusion Criteria:

Disease-Specific Concerns:

  1. Creatinine >4.0mg/dl
  2. Respiratory failure requiring mechanical ventilatory support
  3. Previous treatment with rituximab (Rituxan® ) within 6 months of screening
  4. History of severe allergic or anaphylactic reaction or serious infusion reaction while receiving rituximab
  5. Failure to respond to previous course of rituximab (Rituxan®) administered for treatment of GPA, as determined by the discretion of the PI

5. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies 6. Use of the maintenance immunosuppressive agent (methotrexate, azathioprine, mycophenolate mofetil or leflunomide) within 5 drug half-lives prior to baseline 7. Treatment with any other biologic agent, including belimumab, within the past 3 months of screening 8. Treatment with cyclophosphamide (oral or intravenous) within the past 1 month of screening

General Medical Concerns:

  • Pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment), or lactating.
  • Inability to comply with study and/or follow-up procedures.

Rituximab-Specific Concerns:

  • History of HIV.
  • Presence of active infection..
  • New York Heart Association Classification III or IV heart disease (See Appendix D).
  • Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
  • History of psychiatric disorder.
  • At the Investigator's discretion, receipt of a live vaccine within 4 weeks prior to randomization.

Positive hepatitis B or C serology is considered a potential exclusion criterion. Hepatitis B screening should include hepatitis B surface antigen (HBsAg) and core antibody (anti-HBc) in all patients. For patients who show evidence of prior hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before and/or during Rituxan treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Rituximab Arm
All subjects in this arm will receive standard of care induction therapy, and then will receive two additional rituximab infusions at week 16 and week 32.
Drug: Rituximab
Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
Other Names:
  • Rituxan
Placebo Comparator: Placebo Arm
All subjects in this arm will receive standard of care induction therapy, and then will receive two additional placebo infusions at week 16 and week 32.
Other: Placebo
Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients in ENT remission without relapse at week 52 in each treatment group.
Time Frame: Assessed at week 52
ENT remission is defined as a GPA ENT disease activity score of 0.
Assessed at week 52

Secondary Outcome Measures

Outcome Measure
Time Frame
Comparison of mean ENT disease activity scores between treatment arms
Time Frame: Assessed at week 52
Assessed at week 52
Cumulative steroid dose
Time Frame: Assessed at week 52
Assessed at week 52
Duration of steroid free remission
Time Frame: Assessed at week 52
Assessed at week 52
Proportion of subject in remission without relapse and completed steroid taper
Time Frame: Assessed at week 52
Assessed at week 52
Quality of Life as measured by the SNOT-22 Questionnaire
Time Frame: Assessed at week 0, 16, and 52
Assessed at week 0, 16, and 52
Change in VDI in the ENT domain
Time Frame: Assessed at week 52
Assessed at week 52
Number of surgical procedures in the ENT domain required during the study period
Time Frame: Assessed at week 52
Assessed at week 52
Number of ENT flares as measured by the ENT GPA DAS
Time Frame: Assessed at week 52
Assessed at week 52
Number of GPA flares as measured by BVAS-WG
Time Frame: Assessed at week 52
Assessed at week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital for Special Surgery, New York

Collaborators

Roche Pharma AG
Genentech, Inc.

Investigators

  • Principal Investigator: Robert F Spiera, MD, Hospital for Special Surgery, New York

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2015

Primary Completion (Actual)

July 1, 2017

Study Completion (Actual)

July 1, 2017

Study Registration Dates

First Submitted

December 8, 2015

First Submitted That Met QC Criteria

December 9, 2015

First Posted (Estimate)

December 10, 2015

Study Record Updates

Last Update Posted (Actual)

March 22, 2018

Last Update Submitted That Met QC Criteria

March 20, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2015-424

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Granulomatosis With Polyangiitis (Wegener's Granulomatosis)

Clinical Trials on Rituximab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe